P. Nelson, B. Mathers, B. Cowie, H. Hagan, D. Jarlais et al., Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, The Lancet, vol.378, issue.9791, pp.571-83, 2011.
DOI : 10.1016/S0140-6736(11)61097-0

P. Leclerc, A. Vandal, A. Fall, J. Bruneau, E. Roy et al., Estimating the size of the population of persons who inject drugs in the island of Montr??al, Canada, using a six-source capture???recapture model, Drug and Alcohol Dependence, vol.142, pp.174-80, 2014.
DOI : 10.1016/j.drugalcdep.2014.06.022

P. Leclerc, C. Morissette, and C. Tremblay, Le volet montréalais du Réseau SurvUDI, Données au 31 mars 2011 Montréal (QC): Direction de santé publique ?Agence de la santé et des services sociaux de Montréal, 2013.

A. Myles, G. Mugford, J. Zhao, M. Krahn, and P. Wang, Physicians??? Attitudes and Practice Toward Treating Injection Drug Users Infected with Hepatitis C Virus: Results from a National Specialist Survey in Canada, Canadian Journal of Gastroenterology, vol.25, issue.3, pp.135-144, 2011.
DOI : 10.1155/2011/810108

R. Moirand, M. Bilodeau, S. Brissette, and J. Bruneau, Determinants of Antiviral Treatment Initiation in a Hepatitis C-infected Population Benefiting from Universal Health Care Coverage, Canadian Journal of Gastroenterology, vol.21, issue.6, pp.355-61, 2007.
DOI : 10.1155/2007/576765

M. Manns, J. Mchutchison, S. Gordon, V. Rustgi, M. Shiffman et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-65, 2001.
DOI : 10.1016/S0140-6736(01)06102-5

M. Fried, M. Shiffman, K. Reddy, C. Smith, G. Marinos et al., Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.347, issue.13, pp.975-82, 2002.
DOI : 10.1056/NEJMoa020047

L. Bernier, B. Willems, G. Delage, and D. Murphy, Identification of numerous hepatitis C virus genotypes in Montreal, Canada, J Clin Microbiol, vol.34, issue.11, pp.2815-2823, 1996.

E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-torres, T. Hassanein et al., Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-87, 2013.
DOI : 10.1056/NEJMoa1214853

N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin et al., Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection, New England Journal of Medicine, vol.370, issue.20, pp.1889-98, 2014.
DOI : 10.1056/NEJMoa1402454

K. Kowdley, S. Gordon, K. Reddy, L. Rossaro, D. Bernstein et al., Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis, New England Journal of Medicine, vol.370, issue.20, pp.1879-88, 2014.
DOI : 10.1056/NEJMoa1402355

N. Afdhal, K. Reddy, D. Nelson, E. Lawitz, S. Gordon et al., Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection, New England Journal of Medicine, vol.370, issue.16, pp.1483-93, 2014.
DOI : 10.1056/NEJMoa1316366

F. Poordad, C. Hezode, R. Trinh, K. Kowdley, S. Zeuzem et al., ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis, New England Journal of Medicine, vol.370, issue.21, pp.1973-82, 2014.
DOI : 10.1056/NEJMoa1402869

S. Zeuzem, I. Jacobson, T. Baykal, R. Marinho, F. Poordad et al., Retreatment of HCV with ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin, New England Journal of Medicine, vol.370, issue.17, pp.1604-1618, 2014.
DOI : 10.1056/NEJMoa1401561

W. Dowdle, The principles of disease elimination and eradication, Bull World Health Organ, vol.76, issue.2, pp.22-27, 1998.

J. Grebely, G. Matthews, A. Lloyd, and G. Dore, Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements, Clinical Infectious Diseases, vol.57, issue.7, pp.1014-1034, 2013.
DOI : 10.1093/cid/cit377

B. Yehia, A. Schranz, and C. Umscheid, The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis, PLoS ONE, vol.46, issue.5, p.101554, 2014.
DOI : 10.1371/journal.pone.0101554.s002

A. Cousien, V. Tran, S. Deuffic-burban, M. Jauffret-roustide, J. Dhersin et al., Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs, Hepatology, vol.8, issue.Suppl 1, pp.1090-101, 2016.
DOI : 10.1002/hep.28227

D. Rolls, G. Daraganova, R. Sacks-davis, M. Hellard, R. Jenkinson et al., Modelling hepatitis C transmission over a social network of injecting drug users, Journal of Theoretical Biology, vol.297, pp.73-87, 2012.
DOI : 10.1016/j.jtbi.2011.12.008

J. Marin, P. Pudlo, C. Robert, and R. Ryder, Approximate Bayesian computational methods, Statistics and Computing, vol.6, issue.31, pp.1167-80, 2012.
DOI : 10.1007/s11222-011-9288-2
URL : https://hal.archives-ouvertes.fr/hal-00567240

R. Myers, H. Shah, K. Burak, C. Cooper, and J. Feld, An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver, Canadian Journal of Gastroenterology and Hepatology, vol.29, issue.1, pp.19-34, 2015.
DOI : 10.1155/2015/692408

A. , I. , and I. ?. Usa, Recommendations for testing, managing, and treating hepatitis C. 2014. [Accessed, 2015.

A. Marshall, S. Saeed, L. Barrett, C. Cooper, C. Treloar et al., Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study, CMAJ Open, vol.4, issue.4, pp.605-619, 2016.
DOI : 10.9778/cmajo.20160008

. Régie-de-l-'assurance-maladie-du-québec, Liste de médicaments, 2015.

L. Wiessing, M. Ferri, B. Grady, M. Kantzanou, I. Sperle et al., Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention, PLoS ONE, vol.375, issue.7, p.103345, 2014.
DOI : 10.1371/journal.pone.0103345.s004

T. Van-de-laar, R. Molenkamp, C. Van-den-berg, J. Schinkel, M. Beld et al., Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam, Journal of Hepatology, vol.51, issue.4, pp.667-74, 2009.
DOI : 10.1016/j.jhep.2009.05.027

A. Sutton, N. Gay, W. Edmunds, V. Hope, O. Gill et al., Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales, BMC Infectious Diseases, vol.330, issue.1, p.93, 2006.
DOI : 10.1136/bmj.38286.841227.7C

M. Hellard, D. Rolls, R. Sacks-davis, G. Robins, P. Pattison et al., The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs, Hepatology, vol.138, issue.Suppl 1, pp.1861-70, 2014.
DOI : 10.1002/hep.27403

M. Hellard, R. Jenkinson, P. Higgs, M. Stoove, R. Sacks-davis et al., Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia, The Medical Journal of Australia, vol.196, issue.10, pp.638-679, 2012.
DOI : 10.5694/mja11.10981

N. Martin, P. Vickerman, J. Grebely, M. Hellard, S. Hutchinson et al., Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals, Hepatology, vol.42, issue.5, pp.1598-609, 2013.
DOI : 10.1002/hep.26431

N. Martin, M. Hickman, S. Hutchinson, D. Goldberg, and P. Vickerman, Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy, Clinical Infectious Diseases, vol.57, issue.suppl 2, pp.39-45, 2013.
DOI : 10.1093/cid/cit296

J. Cox, C. Morissette, P. De, C. Tremblay, R. Allard et al., Access to Sterile Injecting Equipment is More Important Than Awareness of HCV Status for Injection Risk Behaviors Among Drug Users, Substance Use & Misuse, vol.61, issue.1, pp.548-68, 2009.
DOI : 10.1016/S0376-8716(00)00144-7

P. Korthuis, D. Feaster, Z. Gomez, M. Das, S. Tross et al., Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness, Addictive Behaviors, vol.37, issue.4, pp.552-557, 2012.
DOI : 10.1016/j.addbeh.2011.12.001

H. Thein, W. Isaranuwatchai, M. Campitelli, J. Feld, E. Yoshida et al., Health care costs associated with hepatocellular carcinoma: A population-based study, Hepatology, vol.50, issue.4, pp.1375-84, 2013.
DOI : 10.1002/hep.26231

P. De, Using social networks to better conceptualize risk fro bloodborne viruses among injection drug users. Montréal: McGill university, 2007.

E. Roy, J. Boudreau, and J. Boivin, Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience, Drug and Alcohol Dependence, vol.102, issue.1-3, pp.1-3158, 2009.
DOI : 10.1016/j.drugalcdep.2009.01.006

E. Roy, N. Haley, P. Leclerc, B. Sochanski, J. Boudreau et al., Mortality in a Cohort of Street Youth in Montreal, JAMA, vol.292, issue.5, pp.569-74, 2004.
DOI : 10.1001/jama.292.5.569

A. Au-ministre-de-l, Institut National d'Excellence en Santé et Services Sociaux pour la mise à jour des listes de médicaments, 2015.

T. French, M. Cooperative-study, and . Group, Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C, Hepatology, vol.20, issue.1, pp.15-20, 1994.

E. Fazito, P. Cuchi, M. Mahy, and T. Brown, Analysis of duration of risk behaviour for key populations: a literature review, Sexually Transmitted Infections, vol.88, issue.Suppl 2, pp.24-32, 2012.
DOI : 10.1136/sextrans-2012-050647